Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 4, 2026, 12:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Control Study Product Clear all
Completed Early Phase 1 Interventional

Intraoperative Ketamine for Patients Undergoing Total Joint Arthroplasty

NCT04437888
View directory record Official record
Conditions
Pain, Postoperative, Arthroplasty Complications
Interventions
Ketamine
Drug
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Sep 26, 2024 · Synced Sep 4, 2026, 12:23 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Relationship Between HbA1c and Chronic Glycemia in Patients With Cirrhosis

NCT02389127
View directory record Official record
Conditions
Cirrhosis, Diabetes Mellitus, Type 2
Interventions
Continuous glucose monitor (Dexcom, San Diego, CA)
Device
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2017 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Not applicable Interventional Results available

Absorb IV Randomized Controlled Trial

NCT02173379
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenosis, Coronary Disease, Coronary Stenosis
Interventions
Absorb BVS, XIENCE
Device
Lead sponsor
Abbott Medical Devices
Industry
Eligibility
18 Years and older
Enrollment
2,604 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
98
States / cities
Birmingham, Alabama • Chandler, Arizona • Gilbert, Arizona + 82 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2023 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Steroids in Bilateral Total Knee Replacement

NCT01399268
View directory record Official record
Conditions
Postoperative Inflammatory Response
Interventions
Hydrocortisone, Saline
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
50 Years to 90 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 30, 2017 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Extension of Phase 3 Gene Therapy for Painful Diabetic Neuropathy

NCT04055090
View directory record Official record
Conditions
Painful Diabetic Neuropathy, Diabetic Neuropathy, Painful
Interventions
Long-Term Follow-Up of Patients who Received Engensis (VM202), Long-Term Follow-Up of Patients who Received Placebo
Genetic · Drug
Lead sponsor
Helixmith Co., Ltd.
Industry
Eligibility
18 Years to 75 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
14
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Sacramento, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2025 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Perioperative Administration of Tranexamic Acid for Placenta Previa and Accreta Study

NCT02806024
View directory record Official record
Conditions
Placenta Accreta, Postpartum Hemorrhage, Cesarean Section, Tranexamic Acid
Interventions
Tranexamic Acid, Placebo Drug
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2019 · Synced Sep 4, 2026, 12:23 AM EDT
Withdrawn Not applicable Interventional

Pendulum D2D Glucose Control for Adults With Type 2 Diabetes

NCT04228003
View directory record Official record
Conditions
Type2 Diabetes, Gastrointestinal Symptoms
Interventions
Pendulum Glucose Control formulation for T2D
Dietary Supplement
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

A Study of Sotatercept for the Treatment of Pulmonary Arterial Hypertension (MK-7962-003/A011-11)(STELLAR)

NCT04576988
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Sotatercept, Placebo, Background PAH Therapy
Biological · Drug
Lead sponsor
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA
Industry
Eligibility
18 Years and older
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
39
States / cities
Phoenix, Arizona • Tucson, Arizona • San Diego, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Insulin Glulisine on Top of Insulin Glargine With or Without Metformin in Type 2 Diabetic Patients

NCT01768559
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Insulin glulisine QD, Insulin glulisine TID, Insulin Glargine (Mandatory background drug), Metformin (Background drug)
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
894 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
46
States / cities
Sun City, Arizona • Tempe, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Jan 3, 2017 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

NCT01038427
View directory record Official record
Conditions
Rhinitis, Allergic, Seasonal
Interventions
Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo
Drug
Lead sponsor
Sandoz
Industry
Eligibility
12 Years and older
Enrollment
795 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
8
States / cities
Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 2Phase 3 Interventional Results available

A Study to Assess the Effect of Cannabidiol Oil on Pain After Ureteroscopy for Kidney Stones

NCT04387617
View directory record Official record
Conditions
Urinary Stone
Interventions
Cannabidiol, Placebo
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 17, 2023 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study of ISIS 681257 (AKCEA-APO(a)-LRx) in Participants With Hyperlipoproteinemia(a) and Cardiovascular Disease

NCT03070782
View directory record Official record
Conditions
Elevated Lipoprotein(a), Cardiovascular Disease
Interventions
ISIS 681257, Placebo
Drug
Lead sponsor
Akcea Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
286 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
22
States / cities
Cottonwood, Arizona • Huntington Beach, California • La Jolla, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants

NCT06716879
View directory record Official record
Conditions
Healthy Participants
Interventions
Donzakimig, Placebo
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Recruiting Phase 4 Interventional Accepts healthy volunteers

Effects of Energy Drinks on Cardiovascular Endpoints

NCT07212803
View directory record Official record
Conditions
Healthy Volunteers, Safety After Oral Intake
Interventions
Energy Drink A + Placebo Capsule, Placebo Drink + Moxifloxacin Capsule, Placebo Drink + Caffeine Capsule, Placebo Drink + Placebo Capsule, Energy Drink B, Control Product + Taurine, Control Product + Caffeine + Taurine, Lower Dose Energy Drink A
Dietary Supplement · Drug · Other
Lead sponsor
University of the Pacific
Other
Eligibility
18 Years to 40 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Stockton, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2025 · Synced Sep 4, 2026, 12:23 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

An Efficacy Trial in the Research Area of Gastrointestinal Health & Bloating

NCT05418127
View directory record Official record
Conditions
Gastrointestinal Dysfunction
Interventions
Active, Placebo
Dietary Supplement · Other
Lead sponsor
Coconut Goodness Food Products Inc.
Industry
Eligibility
25 Years to 54 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Sep 4, 2026, 12:23 AM EDT
Active, not recruiting Phase 2 Interventional

A Study of Berubicin in Adult Subjects With Recurrent Glioblastoma Multiforme

NCT04762069
View directory record Official record
Conditions
Glioblastoma Multiforme, Adult
Interventions
Berubicin, Lomustine
Drug
Lead sponsor
CNS Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
32
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 28 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

NCT01874366
View directory record Official record
Conditions
Overweight, Diabetes Mellitus Type 2 in Obese
Interventions
P11187, Placebo
Drug
Lead sponsor
Piramal Enterprises Limited
Industry
Eligibility
18 Years to 70 Years
Enrollment
96 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Aug 27, 2014 · Synced Sep 4, 2026, 12:23 AM EDT
Active, not recruiting Phase 2 Interventional

Study of IPMN Progression Prevention With Tocotrienol (SIPP-T3)

NCT06519097
View directory record Official record
Conditions
Neoplasm of Pancreas, IPMN, Pancreatic
Interventions
Vitamin E Delta Tocotrienol, Placebo
Drug · Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tampa, Florida • Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 12, 2025 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 2 Interventional

A Phase 2 Study to Evaluate the Safety and Efficacy of CB-03-01 Solution, a Comparator Solution and Vehicle Solution in Males With Androgenetic Alopecia

NCT02279823
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
CB-03-01 solution, Minoxidil Solution 5%, Placebo solution
Drug
Lead sponsor
Intrepid Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Mar 12, 2017 · Synced Sep 4, 2026, 12:23 AM EDT
Not yet recruiting Phase 1 Interventional

A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma

NCT07422896
View directory record Official record
Conditions
Glioblastoma
Interventions
B-cell vaccination
Biological
Lead sponsor
Catalina Lee Chang
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 4 Interventional Results available

Orphenadrine and Methocarbamol for LBP

NCT02665286
View directory record Official record
Conditions
Low Back Pain
Interventions
Orphenadrine, Methocarbamol, Naproxen, Placebo
Drug
Lead sponsor
Montefiore Medical Center
Other
Eligibility
18 Years to 69 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Randomized, Placebo-controlled Study to Evaluate Effects of E5555 on Renal Function Parameters and OCT2 Activity

NCT01241669
View directory record Official record
Conditions
Healthy Subjects
Interventions
E5555
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2010
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jul 10, 2014 · Synced Sep 4, 2026, 12:23 AM EDT
Withdrawn No phase listed Observational

RANOLAZINE STUDY: Speckle Tracking Derived Myocardial Strain

NCT03257683
View directory record Official record
Conditions
Severe Coronary Artery Disease, Ischaemic Myocardial Dysfunction
Interventions
Ranolazine
Drug
Lead sponsor
Saint Thomas Health
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Apr 9, 2018 · Synced Sep 4, 2026, 12:23 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Intestinal Inflammatory and Metabolic Responses to a High Fat Meal and Plant Polyphenol Blend

NCT03309982
View directory record Official record
Conditions
Anthocyanins
Interventions
Plant polyphenol blend, Placebo
Dietary Supplement · Other
Lead sponsor
Pharmanex
Industry
Eligibility
18 Years to 35 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Apr 19, 2018 · Synced Sep 4, 2026, 12:23 AM EDT